Association of HMG-CoA reductase inhibitors with neuropathy.
OBJECTIVE
To review the possible association between statins and peripheral neuropathy.


METHODS
Literature was obtained from MEDLINE (1984-September 2002) and International Pharmaceutical Abstracts (1970-June 2002). Key search terms included statin, neuropathy, and HMG-CoA reductase inhibitor.


RESULTS
Epidemiologic studies and case reports suggest an increased risk of peripheral neuropathy with statin drugs. Most patients were receiving long-term therapy, although the onset was highly variable. The majority of cases were at least partially reversible with drug cessation. Specific risk factors or mechanisms have not been identified.


CONCLUSIONS
Observational data suggest a link between chronic statin use and increased risk of peripheral neuropathy. However, the risk appears to be small relative to the significant cardioprotective benefits.
Backes
James M
JM
Department of Pharmacy Practice and Lipid, Atherosclerosis, Metabolic and LDL-Apheresis Clinic, University of Kansas Medical Center, Kansas City, KS 66160-7231, USA. jbackes@kumc.edu
Howard
Patricia A
PA
D000328:Adult; D000368:Aged; D005260:Female; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D010523:Peripheral Nervous System Diseases / Q000139:chemically induced*; D012307:Risk Factors; D013997:Time Factors
D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors